LungLife AI, Inc.
LSE: LLA.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Paul Pagano
- Employees
- 8
- Headquarters
- Thousand Oaks, United States
- IPO year
- 2024
- Market cap
- £1.3M
- Website
- https://lunglifeai.com
Loading LLA…
Loading profile data…Frequently asked questions about LLA
What does LungLife AI, Inc. (LLA.L) do?
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The...
Where does LLA.L trade?
LungLife AI, Inc. (LLA.L) trades on the London Stock Exchange.
What sector is LLA.L in?
LungLife AI, Inc. (LLA.L) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of LungLife AI, Inc.?
Paul Pagano is the chief executive officer of LungLife AI, Inc. (LLA.L).
Where is LungLife AI, Inc. headquartered?
LungLife AI, Inc. is headquartered in United States.
Does LLA.L pay a dividend?
LungLife AI, Inc. (LLA.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LLA.L go public?
LungLife AI, Inc. (LLA.L) completed its initial public offering in 2024.